drugset / Trial / NCT00502242

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

NCT00502242

Phase 4 Completed 229 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to determine the efficacy of ramipril in preventing a urinary protein to creatinine ratio (U p/c) greater than 0.5 following conversion to sirolimus from a calcineurin inhibitor (CNI) in maintenance kidney transplant patients.

Timeline

Start
2007-12
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ramipril Small molecule 5 mg Oral

Indications

No indication recorded.